Tech News · The field notes
Personal Tech — Wednesday, October 28, 2026
SK hynix posts a record chip quarter, chip stocks rally on Meta and Oracle deals, Meta's share sale is five times oversubscribed, a sixty-three-billion-dollar Broadcom financing backs Anthropic, and Microsoft and Alphabet report earnings tonight.
SK hynix record preliminary Q3 2026
- operating profit 83.3 trillion won, up 632% YoY
- revenue 104.6 trillion won, up 328%
- 80% operating margin
- net profit down QoQ on non-operating items
- 14 major customers' long-term agreements cover >half of 2027-2028 capacity
- demand > supply through 2030 is a company forecast
- 14 trillion won dividend + 20 trillion won buyback
Chip-stock rally Oct 27-28
- AMD +5.45% on Helios systems running at Meta + $1B investment in Meta offering
- Intel gains on expanded Oracle partnership (Xeon, future Diamond Rapids X14 systems for Oracle Cloud)
- Nvidia $3B investment in Meta offering
Meta share sale
- upsized $25B offering reportedly 5x oversubscribed
- combined 2026 capex guidance for Alphabet, Amazon, Microsoft, Meta roughly $725-745B
Earnings day
- Microsoft + Alphabet report after close Wed Oct 28 (MSFT consensus ~$4.71 EPS, ~$90.6B revenue, Azure ~45% guided
- Alphabet ~$3.03 EPS, ~$127.9B revenue, Google Cloud in focus)
- Amazon Thu Oct 29
- Fed rate decision Wed afternoon (markets expect hold at 3.75-4.00%)
- caution that Q2 headline EPS at all three was inflated by AI-lab investment gains
Earnings concentration
- FactSet S&P 500 Q3 growth ~29% blended, falling to ~20% without Micron and Nvidia
Anthropic infrastructure financing
- banks + Blackstone commit $63B vehicle to buy Broadcom accelerators/networking and lease to Anthropic, deliveries from 2027
- debt/lease scrutiny of AI build-out funding
Funding
- Physical Intelligence in talks to raise $1B+ at up to ~$20B valuation (nearly double earlier 2026 $11.5B round
- reportedly no revenue
- ex-DeepMind/Stanford/Berkeley founders
- robot model opened to external developers Oct 2026)
- Vera Health $28.5M Series A led by Threshold Ventures (Optum Ventures, Mantis VC, SV Angel
- 800,000 clinicians
- $32M total)
- Nevis $70M Series B led by EQT Ventures (AI OS for wealth management
- $110M total in 2 years)
- Atlas Bio $12.5M launch from stealth led by Creandum (AI foundation model for in silico clinical trials
- ~2M human RNA readouts
- aims to replace Phase II trials costing $100M+, 2-3 years, ~70% fail rate, with 12-week simulations
- first trial results expected within 6 weeks)